[Daily Medi] Heart Disease Diagnostic Medical Device AMCG Challenges KONEX

☞ Go to article

Heart disease diagnostic medical device company AMCG is challenging entry into the KONEX market.

According to the Korea Exchange, AMCG submitted an application for new listing on the KONEX market on November 20. The designated advisor is Daishin Securities.

Founded in March 2021, AMCG is a company that develops diagnostic test medical devices and reading solutions for heart disease. 

It has developed a magnetocardiography system 'MCG (Magneto cardio graphy)' that can perform various tests for heart disease diagnosis quickly and accurately.

The MCG system is a magnetocardiography diagnostic system that can accurately diagnose heart disease without drug or radiation injection by using tiny magnetic fields from the human body. 

It has higher accuracy than electrocardiogram tests that analyze heart movements in waveform, and is particularly specialized for early diagnosis of angina patients and chemotherapy-induced cardiomyopathy.

Also, while existing heart disease tests require various examinations, long time, and high costs, the MCG system has less risk of side effects because it doesn't use radiation or contrast agents, according to the company.

The MCG system received item approval from the Ministry of Food and Drug Safety in June 2022 and is currently conducting Phase 4 clinical trials to evaluate diagnostic accuracy for patients suspected of coronary artery disease at Gachon University Gil Hospital and Eunpyeong St. Mary's Hospital. It is also expanding clinical institutions and additional indications.

[Daily Medi Reporter Koo Kyo-yoon]